The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.

@article{Frieder2018TheIO,
  title={The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.},
  author={Jillian Frieder and D Kivelevitch and Connie Tran Fiore and Saadeddine Saad and Alan Menter},
  journal={Expert review of clinical immunology},
  year={2018},
  volume={14 1},
  pages={
          1-19
        }
}
INTRODUCTION Psoriasis is a common, immune-mediated skin disease often associated with significant physical and psychosocial impairment. Antipsoriatic biologic agents offer patients unparalleled treatment potential in regard to greater skin clearance and overall improved quality of life. Evaluation of the therapeutic efficacy of biologic agents on the full psoriasis disease burden must account for their impact on both physical symptoms, as well as patient-reported, health-related quality of… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 155 REFERENCES

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

  • The New England journal of medicine
  • 2016
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

A systematic review of worldwide epidemiology of psoriasis.

  • Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2017
VIEW 1 EXCERPT